Sun Pharma, Samsung BioLOgics Tie-Up To Manufacture Tildrakizumab


Sun Pharmaceutical Industries Ltd and Samsung BioLogics has entered into a strategic long-term manufacturing agreement for Tildrakizumab. The agreement was entered into by Sun Pharma’s wholly-owned subsidiary and Samsung BioLogics. The approximate value of the contract will be USD 55.5 million.

According to the agreement, Sun Pharma has appointed Samsung BioLogics to manufacture Tildrakizumab, an investigational IL-23p19 inhibitor being evaluated for the treatment of moderate to severe plaque psoriasis.

Filings for this novel investigational biologic has been accepted for review by the USFDA in May and the European Medicines Agency (EMA) in March 2017. Meanwhile, the stock opened in green, gaining 0.45% at Rs 554.95 per share on BSE on Monday’s trade.

For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 
Give a Missed Call for Free Trial - 09699997717 
Share on Google Plus

About Suhani Varma

This is a short description in the author block about the author. You edit it by entering text in the "Biographical Info" field in the user admin panel.

0 comments: